中文摘要：如今，耐多药（MDR）细菌的出现被认为是公共卫生面临的最大挑战之一。随着传统抗菌素的失效和新型抗生素的研究日益减少，耐多药细菌的一些替代疗法受到了越来越多的关注。噬菌体疗法便是其中之一，并提供了一个有希望减少后抗生素时代的细菌感染负担的机会。本文综述了目前支持噬菌体疗法对抗呼吸医学中流行或新出现的耐多药细菌病原体的证据，以及临床前数据生成面临的挑战。本文首先讨论了如何改进噬菌体在肺表面的输送，接着讨论了有关呼吸道感染疗效数据的动物模型的最新进展，最后总结了迄今为止所进行的部分人体试验的结果。
外文摘要：The emergence of multi-drug resistant (MDR) bacteria is recognised today as one of the greatest challenges to public health. As traditional antimicrobials are becoming ineffective and research into new antibiotics is diminishing, a number of alternative treatments for MDR bacteria have been receiving greater attention. Bacteriophage therapies are being revisited and present a promising opportunity to reduce the burden of bacterial infection in this post-antibiotic era. This review focuses on the current evidence supporting bacteriophage therapy against prevalent or emerging multi-drug resistant bacterial pathogens in respiratory medicine and the challenges ahead in preclinical data generation. Starting with efforts to improve delivery of bacteriophages to the lung surface, the current developments in animal models for relevant efficacy data on respiratory infections are discussed before finishing with a summary of findings from the select human trials performed to date.
外文关键词：multi-drug resistance；bacteriophage；respiratory；infectious disease
作者：Iszatt, JJ；Larcombe, AN；Chan, HK；Stick, SM；Garratt, LW；Kicic, A
作者单位：Curtin Univ；Telethon Kids Inst；Univ Sydney；Perth Childrens Hosp；Univ Western Australia
期刊名称：VIRUSES-BASEL
期刊影响因子：3.816
出版年份：2021
出版刊次：9
点击下载：噬菌体治疗耐多药呼吸道感染